Optipharma

Optipharm is a South Korean biotechnology company specializing in xenotransplantation, vaccine development, and bacteriophage technology. The company is a leader in the development of transgenic miniature pigs (Medipigs) designed for organ, tissue, and cell transplantation into humans, with a focus on minimizing immune rejection through genetic engineering. Optipharm's R&D pipeline includes xenogenic kidneys, hearts, and livers, as well as virus-like particle (VLP) vaccines for human and animal health, including a cervical cancer vaccine. Additionally, the company commercializes bacteriophage products for animal health and is expanding into human therapeutics for multi-drug resistant bacterial infections. Listed on the KOSDAQ, Optipharm operates at the intersection of animal and human medicine to address the global shortage of donor organs and emerging infectious diseases.